Press Release: Stereotaxis receives FDA clearance of Vdrive with V-Loop system
Stereotaxis touts FDA win for robotic platform’s catheter manipulator
Missouri-based Stereotaxis (NSDQ:STXS) announced FDA clearance for its V-Loop product, the 2nd model from its Vdrive platform to make it to the U.S. market.
Stereotaxis escapes all shareholder lawsuits
Surgical robotics maker Stereotaxis (NSDQ:STXS) announced week that it’s officially clear of all shareholder litigation after a pair of lawsuits quietly closed this year.
Zimmer executive takes top job at Smiths Medical | Personnel Moves
Smiths Medical president Srini Seshadri is expected to step down, and Zimmer (NYSE:ZMH) executive Jeff McCaulley will step into the top office.
There was no reason given for Seshadri’s departure. He joined the company in 2006 and helped navigate some tough times when it was under-performing, Smiths said.
Rights offering raises $10M for Stereotaxis
Stereotaxis (NSDQ:STXS) said today that a subscription rights offering brought in about $10.2 million in gross proceeds.
A subscription rights offering allows existing shareholders to acquire stock in a company, usually at a discount.
Stereotaxis jumps on Japanese reimbursement win, releases Q3 prelims
Stereotaxis won Japan’s highest reimbursement classification for its Niobe magnetic navigation system.
The Niobe system is now classified as a C2 medical device by Japan’s Ministry of Health, Labor & Welfare, according to a press release.
EndoStim takes funding round to $11M | Wall Street Beat
EndoStim added another tranche to its $16.5 million equity round, according to a regulatory filing, saying it’s added some $11.2 million to its coffers as it develops a pacemaker-like implant to treat gastro-esophageal reflux disease.
Former Boston Scientific VP joins InspireMD board | Personnel Moves
St. Jude Medical seesaws on FDA warning letter
A warning letter from the FDA to St. Jude Medical (NYSE:STJ) sent the St. Paul, Minn.-based medical device company’s stock on a seesaw ride yesterday and today.
STJ shares closed up 1.5% yesterday at $38.85 each after St. Jude revealed the warning letter, but closed down 1.2% today at $38.39 apiece.
Amedica promotes Bryan McEntire to chief tech exec | Personnel Moves
Accuray slides on lowered sales outlook | Earnings Roundup
Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.
The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.
